Since its inception, the Allison Institute has strategically recruited top-tier scientists whose work spans immunotherapy resistance, cancer vaccines, cellular and protein engineering, and tumor evolution. The newly appointed members represent a broad spectrum of research foci that address some of the most pressing challenges in oncology. By leveraging innovative methodologies such as chromatin remodeling analysis, mRNA delivery systems, and molecular glue technologies, these researchers aim to dissect the molecular and cellular underpinnings that govern immune evasion and therapeutic resistance in cancer.

Eric Gardner, joining as an assistant member, comes from Weill Cornell Medicine to lead research in the Thoracic/Head & Neck Medical Oncology division. His work delves into the dynamic processes of tumor evolution and plasticity, particularly in lung cancer, where tumor cells adapt to evade immune surveillance. Gardner’s lab examines how alterations in tumor cell state, through mechanisms like chromatin remodeling and lineage plasticity, contribute to the emergence of immunotherapy resistance. Understanding these adaptive processes is critical to developing strategies that sustain durable immune control over malignancies, a central goal of the Allison Institute’s resistance-focused research efforts.

Betty Kim, a core member and professor of Neurosurgery at MD Anderson, brings a focused expertise on brain tumors, specifically glioblastoma, one of the most aggressive and treatment-resistant cancers. Her laboratory harnesses avant-garde technologies including mRNA-loaded extracellular vesicles and nano-enabled delivery platforms to modulate antitumor immune responses within the central nervous system. Kim’s work sits at the intersection of cancer immunology and neuro-oncology, seeking not just to understand tumor immunodynamics but to pioneer innovative therapeutic avenues that can penetrate the blood-brain barrier and reprogram immune activity in the tumor microenvironment.

Rodrigo Romero, also joining as an assistant member from Memorial Sloan Kettering Cancer Center, investigates tumor lineage plasticity and its impact on disease progression in prostate cancer. His research emphasizes the use of engineered model systems to decode how a constellation of genetic and epigenetic factors — including tumor suppressor gene loss, chromatin modulation, and microenvironmental cues — enables tumor cells to transit between phenotypic states that evade both targeted and immune therapies. Romero’s investigations provide vital insights into the interplay between tumor evolution and immunotherapeutic efficacy, fostering novel approaches that could mitigate resistance in prostate and other cancers.

Hojong Yoon, who joined the Allison Institute in 2025 as an assistant member, is an expert in intracellular signaling pathways that orchestrate immune cell functions within the tumor milieu. Transplanted from the Broad Institute

In a groundbreaking review article published in the prestigious journal Molecular Biomedicine, researchers from Shanghai Jiao Tong University School of Medicine present an exhaustive synthesis of emerging single-cell multi-omics technologies that are revolutionizing BTC research. These state-of-the-art techniques integrate genomic, transcriptomic, epigenomic, and proteomic data at the resolution of individual cells, thereby illuminating the heterogeneity of tumor tissues with unprecedented clarity. This integrative approach enables scientists to dissect the cellular constituents, molecular features, and dynamic interactions within tumors, fostering a comprehensive atlas that can inform and transform clinical management strategies.

Single-cell multi-omics methodologies delve deeply into the distinct molecular subtypes that coexist within BTC tumors, revealing the clonal architecture and evolutionary pathways that define tumor progression. By mapping these heterogeneous populations, the studies elucidate how specific genetic mutations, gene expression patterns, and epigenetic modifications contribute to tumor biology. Such detailed cellular profiling holds the promise of identifying novel biomarkers predictive of disease course and therapeutic response, ultimately paving the way for highly personalized oncological interventions.

One of the pivotal insights emerging from this review highlights the intricate composition of the tumor microenvironment (TME), a complex ecosystem that encompasses a diverse array of cancer-associated fibroblasts (CAFs), immune cell populations, endothelial cells, and extracellular matrix components. Among CAFs, functional heterogeneity is particularly notable, with myofibroblastic CAFs (myoCAFs) implicated in driving angiogenesis through hepatocyte growth factor (HGF) and transforming growth factor-beta (TGF-β) signaling cascades. In contrast, inflammatory CAFs (iCAFs) secrete cytokines such as interleukin-6 (IL-6) and vascular endothelial growth factor A (VEGFA), promoting an inflammatory milieu that fosters tumor progression and immune modulation.

Moreover, single-cell analyses have shed light on the diverse immune cell subsets within BTCs, including tumor-infiltrating lymphocytes and macrophages, which engage in complex cross-talk with both tumor cells and stromal elements. The immune microenvironment’s spatial and functional heterogeneity affects tumor immunogenicity and resistance to immune checkpoint blockade therapies. Understanding the mechanistic underpinnings of immune evasion, facilitated by metabolic reprogramming and epigenetic alterations within tumor and stromal cells, is critical for devising effective immunotherapeutic strategies.

The application of single-cell multi-omics data has also revealed the dynamic metabolic states of tumor cells, illustrating how metabolic plasticity supports survival, proliferation, and immune escape. Specific metabolic pathways and epigenetic modifications have been identified as contributors to the immunosuppressive TME, representing potential targets for combination therapies designed to disrupt tumor metabolism and restore antitumor immunity. These findings underscore the necessity of multi-layered molecular analyses to capture the full spectrum of tumor biology and therapeutic vulnerabilities.

Mengyao Li, a corresponding author of the review, emphasizes the transformative potential of integrating data across multiple molecular layers. He remarks that such integrative efforts convert the simplistic, averaged view of tumors into a high-resolution, multidimensional atlas that captures cellular diversity and functional states. This refinement is not merely academic; it is foundational for the next frontier in individualized cancer therapy, enabling clinicians to tailor interventions based on the specific cellular and molecular context of each patient’s tumor.

The translation of single-cell multi-omics insights into clinical practice is already underway, with patient-derived organoids (PDOs) emerging as powerful platforms for drug screening and precision medicine. PDOs faithfully recapitulate the molecular heterogeneity and microenvironmental features of primary tumors, allowing for functional assays that predict drug sensitivities and resistances. This application represents a tangible leap toward personalized oncology, bridging bench discoveries with bedside decisions.

Despite remarkable advancements, the review acknowledges that significant hurdles remain. Technical challenges in sample dissociation, particularly from solid tumor tissues, pose limitations on preserving cell viability and capturing rare cell populations. Additionally, the computational complexity inherent in integrating multi-omics datasets demands sophisticated bioinformatic tools and standardized analytical workflows. Addressing these obstacles requires collaborative, large-scale, multi-institutional initiatives that leverage artificial intelligence and machine learning to extract actionable insights from voluminous single-cell data.

The authors advocate for an expanded global effort to generate comprehensive single-cell atlases of BTCs, encompassing diverse patient populations and clinical contexts. Such endeavors will enrich our understanding of disease mechanisms, refine diagnostic criteria, and identify novel therapeutic targets. Collaborative networks combining high-throughput molecular profiling, functional modeling, and clinical trials promise to accelerate the translation of multi-omics knowledge into improved patient outcomes.

Intriguingly, the review also points toward the integration of spatial transcriptomics and imaging mass cytometry with single-cell multi-omics, technologies that add topographical context to molecular data. By preserving spatial relationships among cells within the tumor milieu, researchers can better understand cellular interactions and niche-specific signaling dynamics, key factors in tumor progression and therapy resistance. This comprehensive spatial-molecular mapping will constitute the next milestone in BTC research.

In sum, the synthesis presented by the Shanghai Jiao Tong University team marks a paradigm shift in our approach to biliary tract cancers. Single-cell multi-omics has unveiled the staggering complexity and plasticity of tumor ecosystems, charting new paths from molecular discovery to clinical innovation. As this technology matures and integrates with computational advances, it holds the promise of transforming BTCs from a grim prognosis to a landscape of tailored, effective therapies, reshaping patient care in the gastrointestinal oncology realm.

Subject of Research: Biliary Tract Cancers and Single-cell Multi-omics Technologies

Article Title: Single-cell multi-omics in biliary tract cancers: decoding heterogeneity, microenvironment, and treatment strategies

News Publication Date: 15-Oct-2025

Web References:
10.1186/s43556-025-00330-2

Image Credits: Nannan Tang (Renji Hospital, Shanghai Jiao Tong University School of Medicine)

Keywords: Biliary Tract Cancer, Single-cell Multi-omics, Tumor Heterogeneity, Tumor Microenvironment, Cancer-associated Fibroblasts, Immune Evasion, Metabolic Reprogramming, Epigenetics, Precision Oncology, Patient-derived Organoids, Molecular Subtypes, Immunotherapy